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SMAD4 haploinsufficiency in small intestinal
neuroendocrine tumors
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Martin E. Johansson1, Ola Nilsson1† and Yvonne Arvidsson1*†
Abstract
Background: Patients with small intestinal neuroendocrine tumors (SINETs) frequently present with lymph node
and liver metastases at the time of diagnosis, but the molecular changes that lead to the progression of these
tumors are largely unknown. Sequencing studies have only identified recurrent point mutations at low frequencies
with CDKN1B being the most common harboring heterozygous mutations in less than 10% of all tumors. Although
SINETs are genetically stable tumors with a low frequency of point mutations and indels, they often harbor
recurrent hemizygous copy number alterations (CNAs) yet the functional implications of these CNA are unclear.
Methods: Utilizing comparative genomic hybridization (CGH) arrays we analyzed the CNA profile of 131 SINETs
from 117 patients. Two tumor suppressor genes and corresponding proteins i.e. SMAD4, and CDKN1B, were further
characterized using a tissue microarray (TMA) with 846 SINETs. Immunohistochemistry (IHC) was used to quantify
protein expression in TMA samples and this was correlated with chromosome number evaluated with fluorescent
in-situ hybridization (FISH). Intestinal tissue from a Smad4+/− mouse model was used to detect entero-endocrine
cell hyperplasia with IHC.
Results: Analyzing the CGH arrays we found loss of chromosome 18q and SMAD4 in 71% of SINETs and that focal
loss of chromosome 12 affecting the CDKN1B was present in 9.4% of SINETs. No homozygous loss of chromosome
18 was detected. Hemizygous loss of SMAD4, but not CDKN1B, significantly correlated with reduced protein levels
but hemizygous loss of SMAD4 did not induce entero-endocrine cell hyperplasia in the Smad4+/− mouse model. In
addition, patients with low SMAD4 protein expression in primary tumors more often presented with metastatic
disease.
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Conclusions: Hemizygous loss of chromosome 18q and the SMAD4 gene is the most common genetic event in
SINETs and our results suggests that this could influence SMAD4 protein expression and spread of metastases.
Although SMAD4 haploinsufficiency alone did not induce tumor initiation, loss of chromosome 18 could represent
an evolutionary advantage in SINETs explaining the high prevalence of this aberration. Functional consequences of
reduced SMAD4 protein levels could hypothetically be a potential mechanism as to why loss of chromosome 18
appears to be clonally selected in SINETs.
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Background
Gene mutations contributing to cancer development and
progression are termed driver mutations. For many
tumor types specific driver mutations have been deter-
mined and validated, thus describing molecular mecha-
nisms for tumorigenesis and posing as potential targets
for therapeutic interventions. Small intestinal neuroen-
docrine tumors (SINETs) originate from enterochromaf-
fin (EC) cells in the small intestinal mucosa and are
generally slow-growing neoplasms. Compared to many
tumor types, SINETs are genetically stable with a som-
atic nonsynonymous mutational frequency more than
10-fold lower than that of cutaneous melanomas, squa-
mous cell carcinomas and adenocarcinomas of the lung
[1]. The stability of SINETs in terms of point mutations
is further illustrated by the fact that only a few genes
have been found mutated in more than one patient
tumor. Among recurrently mutated genes CDKN1B has
been reported with the highest frequency, mutated in
only about 7.8–9.6% of all SINETs [2, 3]. Consequently,
for a large proportion of SINETs, no apparent gene
driver mutations have been identified. While recurrent
point mutations have only been identified for a few
genes, SINETs instead harbor several recurrent hemizy-
gous whole chromosomal CNAs [4–6]. The classical
two-hit hypothesis suggests that both alleles of a tumor
suppressor should be inactivated to promote cancer de-
velopment [7]. There are however several prominent ex-
amples of tumor suppressor genes that do not follow
this rule. Two such genes are PTEN [8] and P53 [9],
which have been confirmed to be haploinsufficient,
meaning that cells with one inactivated gene copy does
not maintain their wild-type phenotype. The most fre-
quently occurring genetic alteration in SINETs is hemi-
zygous loss of chromosome 18. SMAD4, located on
chromosome 18, a key conveyer of TGFβ signaling and
found to be mutated in several types of cancer has been
suggested to be haploinsufficient in mouse models [10,
11]. If SMAD4 protein expression is linked to chromo-
some 18 loss this could provide an example of a mech-
anism by which CNAs contribute to SINET
tumorigenesis in the absence of driver mutations. The
overall aim of the present study was to determine if copy
number alterations of SMAD4 and CDKN1B in SINETs
correlate with corresponding protein expression and can
be linked to tumor initiation.
Methods
Array comparative genomic hybridization
One hundred thirty-one fresh-frozen SINET biopsies
from 117 patients including 52 biopsies from 43 patients
previously published [4] were analyzed with array com-
parative genomic hybridization (CGH). One hundred
nine of the 131 CGH analyzed biopsies were also repre-
sented on the tissue microarray used for immunohisto-
chemistry and FISH. The purity of tumor biopsies was
assessed by light microscopy using hematoxylin and
eosin stained sections, and only biopsies with at least
70% tumor cells were analyzed. Genomic DNA was iso-
lated from the biopsies using the DNeasy® Blood and
Tissue kit (Qiagen GmbH, Hilden, Germany). The array
CGH experiments, including labelling and hybridization
of DNA were performed as previously described and ac-
cording to the manufacturer’s protocol (SureTag DNA
Labeling Kit; Agilent Technologies Inc., Palo Alto, CA,
USA) [4]. Array CGH analysis was performed using the
human genome CGH microarray 4x44K (G4410B/
G4426A/G4426B), 2x400K (G4448A), 244 K (G4411B)
and CGH-SNP microarray 4x180K (G4890A) (Agilent
Technologies Inc.). The probes were annotated against
genome build UCSC hg19. Hybridized slides were
scanned on an Agilent High-Resolution Microarray
Scanner followed by data extraction and normalization
using Feature Extraction v.4.0.1.21 (protocol CytoCGH_
0209_1x or 2x or 4x_Mar14) (Agilent Technologies).
Data analysis was carried out using Agilent CytoGe-
nomics 4.0.3.12 (Agilent Technologies Inc.). The ADM-
2 (threshold = 6.0) algorithm was used to identify copy
number aberrations across the genome. A log2 ratio
of ±0.25 and CNAs ≥500 kb was considered as a gain
or loss. A log2 ratio of > 2 was designated as high-
level amplification and a log2 ratio of < − 2 was designated
as homozygous loss. Chromosome arm gains/losses were
determined using a 70% length threshold. The aberrations
were checked manually to confirm the accuracy of the
calls. Known recurrent germline copy number variations
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(Agilent female/male CNV reference) were excluded from
the analysis.
Whole exome sequencing
DNA from 9 fresh-frozen tumors and their corre-
sponding normal samples (small intestine, muscle,
adipose tissue) were extracted using QIAamp DNA
mini kit (Qiagen) and sequencing libraries were pre-
pared using the SureSelect All Exon v3 target enrich-
ment kit (Agilent Technologies, CA). The libraries
were sequenced on an Illumina HiSeq 2000 in paired
end mode with read length 100 bp. After quality trim-
ming using PRINSEQ [12], the reads were aligned to
the human reference genome (hg19) using the BWA-
MEM algorithm (http://bio-bwa.sourceforge.net/).
Marking of duplicates and base recalibration was per-
formed with Picard (https://broadinstitute.github.io/
picard/) and GATK [13], respectively. Single nucleo-
tide variants and small insertions and deletions were
called for the SMAD4 and CDKN1B genes using Hap-
lotypeCaller (germline variants) and Mutect2 (somatic
variants), as implemented in GATK v4.0.8. Only
germline variants with a quality normalized by depth
above five, and somatic variants annotated as PASS,
were considered. Additionally, variants were required
to have a population frequency below 0.10 in the
1000 Genome project.
Tissue microarray (TMA)
The tissue microarray contained 846 tumor biopsies
from 412 patients retrieved from patients who under-
went surgery for SINET at Sahlgrenska University Hos-
pital in the years 1986 to 2013. Details of the
construction of the tissue microarray have previously
been described [14]. The diagnosis of all tumors was re-
validated by staining all tumors for hematoxylin and
eosin, synaptophysin and chromogranin A, and reviewed
by board-certified pathologist (O.N.).
Immunohistochemistry of TMA and Smad4+/− mice
Immunohistochemistry was performed on SINET
TMAs and on gastrointestinal tissue including duode-
num, jejunum, ileum from wild-type Smad4+/+ and
Smad4+/− mice. The Smad4+/− mice were derived
from F5-F8 backcross generations to C57BL/6 of the
original F1 129Ola/C57BL/6Jico SMAD4+/E6sad
founder [15] and was kindly donated by Professor
Riccardo Fodde. Sections (3–4 μm) from formalin-
fixed and paraffin-embedded blocks were placed on
glass slides and treated in Dako PT-Link using EnVi-
sion™ FLEX Target Retrieval Solution (high pH). The
following primary antibodies were used: anti-SMAD4
(B-8, Santa Cruz), anti-p27 (DCS-72.F6, Abcam), anti-
chromogranin A (PHE5, Chemicon and EP1030Y,
Abcam), anti-synaptophysin (SP11, Abcam), anti-5HT
(H209, Dako and LS-B7118, LSBio), and anti-Ki67
(MIB1; Dako). Immunohistochemical staining was
performed in a Dako Autostainer Link using EnVi-
sion™ FLEX according to the manufacturer’s instruc-
tions (DakoCytomation). EnVision™ FLEX+ (LINKER)
rabbit or mouse was used for all stainings. Positive
and negative controls were included in each run. The
fraction of Ki67-positive cells was estimated by manu-
ally counting 500–2000 tumor cells per sample, using
printouts. For relative quantification of SMAD4 and
CDKN1B expression, the total global staining intensity
of tumor cells was assessed, meaning localized subcel-
lular i.e. nuclear or cytoplasmatic staining intensity
was not individually evaluated. A board-certified path-
ologist (O.N.) examined the TMA tissue samples
using a light microscope with a 4× objective until
samples could with a high degree of repeatability be
subcategorized as either ‘None’. ‘Low’, or ‘High’.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) was per-
formed on 4 μm paraffin sections from the tissue
microarray using dual-color fluorescent probes for
SMAD4 and chromosome 18 centromeric region or
CDKN1B and chromosome 12 centromeric region
(FA0590, FA0305, Abnova). Pre-processing of paraffin
sections, hybridization to the probe, post-
hybridization washing and fluorescence detection were
performed according to manufacturer’s instructions
(Abnova). Tumors were examined using an Axioplan
2i epifluorescence microscope (Zeiss, Oberkochen,
Germany). Within each section, normal regions/stro-
mal elements served as the internal control to assess
quality of hybridization. Cases were scored with using
a 100× objective lens, counting at least three distinct
areas and at least 30 discrete nuclei per area. Labeled
nuclei were imaged using an LSM 780 confocal
microscope (Zeiss, Oberkochen, Germany). Bright-
ness/contrast adjustments, scale bar, and image type
transformation were performed using ZEN 3.1.
Statistical analysis
Correlation between protein expression and copy num-
ber status was estimated with Spearman’s rank correl-
ation coefficient. Comparison of the number of CgA-
positive cells in the small intestinal crypts and crypt
bases between Smad4+/− and Smad4+/+ mice was per-
formed using unpaired two-sided Student’s t-test. Com-
parison of SMAD4 expression between tumor sites and
patient disease stages was tested with Mann Whitney U-
test.
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Results
Hemizygous loss of chromosome 18 is the most frequent
chromosomal aberration in SINETs
To investigate and outline recurrent CNAs in SINETs,
we performed copy number analysis on 131 SINETs
from 117 patients, currently the largest investigated
SINET patient cohort. The most frequent CNA was
hemizygous loss of chromosome 18 (71%), consistent
with previous reports [4, 6] (Fig.1a). Tumors with
loss of chromosome 18 and without loss of chromo-
some 18 differed in the type of harbored chromo-
somal alterations. Tumors with loss of chromosome
18 had both fewer gains of whole chromosomes as
well as more losses of whole chromosomes com-
pared to tumors without loss of chromosome 18
(Fig. 1b, c). Some specific chromosomes, including
chromosomes 4, 5, 7, 14, and 20, were more fre-
quently gained in tumors without chromosome 18.
CNAs larger than 500 kb were present in all biopsies
and there was no significant difference in number of
CNAs in SINETs with loss of chromosome 18
(15.2 ± 1.3, N = 93) compared to SINETs without loss
of chromosome 18 (14.7 ± 2.2, N = 38) (Fig. 1d). The
CNA analysis did not detect any homozygous dele-
tion of SMAD4 gene despite the high frequency of
hemizygous loss of chromosome 18. CDKN1B is lo-
cated on chromosome 12 and in contrast to chromo-
some 18, whole chromosome 12 was never lost, but
rather harbored focal events. Among the 117 ana-
lyzed patients, 11 tumors (9.4%) had loss of the
CDKN1B gene. The most frequently lost region that
included the CDKN1B gene was chr12: 11,139,390–
Fig. 1 Copy number alterations (CNAs) in small intestinal neuroendocrine tumors (SINETs). a CGH analysis of 131 SINETs revealed that the most
frequent chromosomal rearrangement is hemizygous loss of chromosomes 9, 13, 18 and 22 and gain of 4, 5, 7, 14 and 20. b and c. Gain of
chromosomes 4, 5, 7, 10, 14 and 20 was more frequent in tumors without hemizygous loss of chromosome 18 (n = 38) compared to SINETs with
hemizygous loss of chromosome 18 (n = 93). (d) The average number of CNAs including all fragments larger than 500 kb was similar in tumors
with (15.2 ± 1.3) or without loss of chromosome 18 (14.7 ± 2.2)
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12,874,937 which contained 28 genes (Suppl.
Fig. 1A–B). In an attempt to identify potential ‘sec-
ond-hit’ mutations in tumors with loss of SMAD4
and CDKN1B we performed whole exome-
sequencing of 9 SINETs and their corresponding
normal samples. These 9 tumors were also included
in the copy number analysis and 7 tumors had loss
of chromosome 18 while none had loss of the
CDKN1B gene. The sequencing analysis revealed that
for these 9 patients no germline or somatic muta-
tions were found neither in the SMAD4 gene nor
the CDKN1B gene.
Hemizygous loss of SMAD4 leads to lower SMAD4 protein
levels
We investigated the SMAD4 and CDKN1B gene copy
number status in 739 and 689 tumors from 373 and
359 patients respectively using fluorescence in situ
hybridization (FISH) on tissue microarrays. As
expected, loss of SMAD4 was frequent with 497/739
tumors (68.1%) having one remaining SMAD4 copy
(Fig. 2a). Gains were rare with only 8/739 tumors
(1.1%) harboring three SMAD4 copies. Loss of
CDKN1B was less frequent compared to SMAD4
loss, with 45/689 (6.8%) tumors having one copy
(Suppl. Fig. 2). CDKN1B gains were also infrequent
with 13/689 tumors (1.9%) harboring three gene cop-
ies. To investigate if SMAD4 and CDKN1B act as
haploinsufficient genes in SINETs we assessed
whether hemizygous loss leads to decreased amounts
of corresponding protein levels. Using immunohisto-
chemistry and FISH, we evaluated the protein stain-
ing intensity of SMAD4 and p27 in relation to gene
copy number status on consecutive tumor sections.
We found that SMAD4 copy number status had a
highly significant correlation to SMAD4 protein
staining intensity (Fig. 2b). The number of CDKN1B
gene copies did however not correlate with the
Fig. 2 Hemizygous loss of SMAD4 was associated with lower SMAD4 protein expression. a Top: Images visualizing FISH analysis with DAPI stained
nuclei (blue) and one respective two Texas red stained copies of the SMAD4 gene (red). Scale bar is equal to 2 μm. Bottom: Images visualizing
biopsies from the TMA representing the expression intensities for scoring None, Low or High SMAD4 expression. b FISH analysis of a tissue
microarray containing 846 tumors from 412 patients showed that hemizygous loss of SMAD4 (68.1%) occurred recurrently in SINETs. Biopsies on
the TMA were both scored for SMAD4 gene copy number by FISH analysis and for SMAD4 protein expression by immunohistochemical staining.
The distribution of SMAD4 protein expression by gene copy number [1–3] is shown. SMAD4 copy number was positively correlated with SMAD4
protein expression
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expression of its corresponding protein, p27 (Suppl.
Fig. 2).
Heterozygous inactivation of Smad4 is not sufficient to
induce hyperplasia in enteroendocrine cells
To investigate if heterozygous Smad4 inactivation could
induce SINET tumorigenesis in mice we used Smad4+/−
genetic mice. These mice spontaneously develop
polyps and adenocarcinomas in the gastrointestinal
tract [10, 11, 15]. In our analysis we focused on chro-
mogranin A (CgA)-positive endocrine cells of the
small intestine. Paraffin-embedded small intestinal tis-
sue samples from the mice were stained with eosin &
hematoxylin, chromogranin A, and serotonin, and
were evaluated by board-certified pathologist (O.N.)
for presence of tumors. In 2/8 heterozygous mice ad-
enomas with low-grade dysplasia was observed. One
sample had a serrated adenoma located in the duode-
num and one sample had two early adenomas with
low-grade dysplasia (Fig. 3a). No tumors of endocrine
origin were observed. In an attempt to identify early
stages of hyperplasia, we quantified the number of
CgA-positive endocrine cells of the intestinal crypts.
We did not observe any differences in the number of
CgA-positive cells in the small intestine of Smad4+/−
and Smad4 wildtype mice (Fig. 3b). Previous studies
have suggested that SINETs originate from CgA-
positive cells in the epithelium at the base of the in-
testinal crypts [16]. We thus also quantified the num-
ber of CgA-positive cells located specifically at the
bottom of the intestinal crypts (up to and including
position + 4), but did again not observe any signifi-
cant difference between the two genotypes (Fig. 3c).
This suggests that heterozygous inactivation of Smad4
in the mouse intestine is not alone sufficient to sus-
tain or drive endocrine cell proliferation.
Patients with lower SMAD4 expression in primary tumors
more frequently present with metastases
The SMAD4 protein expression also differed between
tumor sites. In tumors with only one SMAD4 copy,
SMAD4 protein expression was lowest in primary tu-
mors and lymph node metastasis, while hepatic metasta-
ses showed a higher SMAD4 protein expression
(Fig. 4a). For tumors with two SMAD4 alleles there was
only a significant difference between lymph node metas-
tasis and hepatic metastasis. We also investigated
whether SMAD4 protein expression of the primary tu-
mors could predict if the patient presented with distant
metastases at the time of surgery. SINET patients are
typically staged into disease stages I, IIA, IIB (localized
disease with varying tumor invasion), IIIB (tumors with
any regional lymph node metastasis), and IV (tumors
with any distant metastasis). We found that patients with
lower SMAD4 levels in the primary tumor had more
often metastasized to regional lymph nodes and distant
parts of the body at the time of initial surgery (Fig. 4b).
Finally, there was no correlation between Ki67 index and
expression of SMAD4 (Suppl. Fig. 3).
Discussion
Loss and gain of chromosomes, or aneuploidy, is be-
lieved to be of importance in tumor development. Al-
though most whole-chromosome or chromosome arm
imbalances lead to lower cell fitness when introduced in
an experimental setting [17], they are frequently toler-
ated in cancer cells and about 88% of all cancer types
harbor such events [18]. In fact, a solid tumor on aver-
age harbors about 3 gains and 5 losses at the chromo-
somal arm-level [19, 20]. The highly recurrent character
of SINET copy number changes suggests that these
changes are clonally selected within tumors. Even
though aneuploidy in cancer is a common genetic event,
due to its complexity, the functional implications are not
Fig. 3 Smad4+/− mice did not develop neuroendocrine tumors or display increased endocrine cell proliferation. a One of two low-grade serrated
adenomas found in Smad4+/− mice stained with hematoxylin & eosin, anti-chromogranin A (CgA), anti-serotonin (5-HT), and anti-SMAD4. There
was no observable difference between number of CgA-positive endocrine cells in small intestinal crypts (b) or crypt bases (up to and including
position + 4) (c)
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as well-characterized as specific point mutations. A basic
mechanism by which chromosomal alterations could
affect the phenotypical characteristics of a cell is through
gene dosage, i.e. the number of gene copies influence
corresponding protein expression levels.
Initially, we analyzed 131 tumors from 117 patients for
chromosomal aberrations confirming hemizygous loss at
chromosome 18 as the most common genetic event in
our SINET cohort. We also found that losses of chromo-
somes 9, 13, 18, and 22 and gains of chromosomes 4, 5,
7, 10, 14, and 20 regularly occurred. Chromosome 18
contains the gene encoding the SMAD4 protein that me-
diates TGFβ signaling and the SMAD4 gene is frequently
mutated in several types of malignant tumors resulting
in altered TGFβ signaling and thereby promoting tumor
progression and metastatic capacity [21, 22]. We there-
fore investigated the association between chromosome
18 copies and SMAD4 protein expression in a large
SINET cohort. We observed a significant correlation be-
tween gene copy numbers and protein expression levels
for SMAD4 consistent with a gene dosage mechanism.
We also performed a similar analysis of the CDKN1B
gene located on chromosome 12. As previously men-
tioned, CDKN1B is the most commonly mutated gene in
SINETs, albeit at a low frequency. As we observed sev-
eral segmental losses on chromosome 12 affecting the
CDKN1B gene we therefor hypothesized that hemizy-
gous loss could result in a lower expression of the p27
protein, suggesting that alterations to CDKN1B affected
a greater proportion of SINETs and not only those har-
boring mutations. However, we could not see a similar
association between gene copy numbers and protein ex-
pression levels for p27 in the SINET samples arguing
against a gene dosage mechanism in this context.
Although the functional consequences of reduced
SMAD4 protein levels in SINET are unclear, SMAD4
mutations in other types of cancers shift signaling by
TGFβ from growth inhibiting to cancer promoting [21].
Accordingly, based on the lack of TGFβ binding protein
(LTBP), Chaudry et al. has speculated that midgut carci-
noids are insensitive to TGFβ growth inhibitory effect
[23]. For tumor cells to metastasize they need to go
through a series of changes, including loss of cell polar-
ity and dependence on cell-cell interactions, termed epi-
thelial to mesenchymal transition (EMT). SMAD4
inactivation can lead to an accumulation of nuclear-β-
catenin resulting in overexpression of β-catenin target
genes, promoting EMT and thus metastasis [22, 24]. In
this light, our finding that decreased SMAD4 expression
in primary tumors was associated with the patient pre-
senting with disseminated disease may indicate that this
is an important mechanism also for SINETs. The dis-
crepancy in SMAD4 protein expression between tumor
sites could i.e. be explained by differing tissue environ-
ment conditions and/or genetic intratumoral heterogen-
eity between primary and metastatic tumors observed in
Fig. 4 SMAD4 expression varied by tumor site and lower SMAD4 expression in the primary tumor correlated with the patient presenting with
metastasis at the time of surgery. a Immunohistochemical staining of the SINET tissue microarray revealed that low expression of SMAD4 was
more frequent in both primary tumors and lymph node metastases compared to hepatic metastases for tumors with one SMAD4 copy. b
Comparing SMAD4 protein expression in the primary tumor between patients with localized disease (stage I, IIA, and IIB), lymph node metastases
(stage IIIB), and distant metastases (stage IV) showed that patients with low SMAD4 protein expression in the primary tumors more often
presented with metastatic disease. Asterisks indicate statistically significant changes (Mann Whitney U-test): * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001
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SINETs [25]. Therefore, further mechanistic studies fo-
cused on the effects of disrupted TGFβ-signaling and
SINET metastatic capacity could represent a promising
future research direction.
Germline mutations in SMAD4 can lead to juvenile
polyposis syndrome (JPS), characterized by benign
tumor formation in the gastrointestinal tract and an in-
creased risk of gastrointestinal malignancies. Interest-
ingly, homozygous inactivation is not required for
malignant transformation of JPS-related gastro-enteral
polyps [26] suggesting gene dosage as a possible mech-
anism. Among cancer diseases with the highest SMAD4
alteration frequency are colorectal cancer, pancreatic
cancer, esophageal cancer, and gastric cancer, all origin-
ating in the GI tract (https://www.cancer.gov/tcga) [27].
Also for sporadic small intestinal adenocarcinomas, not
included in most large pan-cancer data-sets, SMAD4 has
been suggested to have a critical role [28].
To determine the effect of heterozygous loss of
SMAD4 on entero-endocrine cell proliferation we quan-
tified intestinal neuroendocrine cells in tissue samples
from a genetic mouse model harboring a Smad4+/−
genotype. We did not detect a higher frequency of enter-
oendocrine cells in the intestinal crypts or find any sign
of enteroendocrine hyperplasia in the Smad4+/− mice
compared to wild-type mice. We suggest that our find-
ings could indicate that loss of chromosome 18 is not a
tumor initiating event but rather represents an early evo-
lutionary advantage during tumor progression. Interest-
ingly, in addition to allelic loss of SMAD4, the genes
BCL2, CDH19, DCC have also been reported as poten-
tial candidate haploinsufficient genes and gains of onco-
gene SRC located on chromosome 20 has previously
been found to correlate with a poorer prognosis [3].
Thus, further explorations regarding the effects of hap-
loinsufficiency and SINET could provide important in-
sights regarding the SINET tumor biology.
Conclusions
In summary, SMAD4 copy number correlated with cor-
responding protein expression in a haploinsufficient
manner. The findings in this study suggest that copy
number alterations in SINET can affect protein expres-
sion of known oncogenes and CNA induced gene-
dosage could represent a novel mechanism regarding
SINET biology. Further research regarding functional
implications of reduced SMAD4 expression in SINETs is
warranted.
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